CrushSCI.com
Journal Selection & Manuscript Polishing Services
Cancer Cell International journal cover Medicine
Back to journal directory

Review Cycle Records

Cancer Cell International

Springer SCIE OA
2026 Emerging Zone 22025 CAS Zone 32025 JCR Q1
193.5Average days
189Median days
74Fastest days
267Longest days
4992025 publications

Paper Review Records

All Paper Review Records

11 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

160 days

Cold atmospheric plasma affects metabolic processes in malignant melanoma

AuthorsErika Rein; Tom Zimmermann; Stefan Fischer; Zubeir El Ahmad; R. Verena Taudte; Arne Gessner; Martin F. Fromm; Melanie Kappelmann-Fenzl; Anja Bosserhoff

Affiliations1. Institute of Biochemistry, University of Erlangen-Nürnberg, Erlangen, Germany; 2. Faculty of Computer Science, Deggendorf Institute of Technology, Deggendorf, Germany; 3. Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany; 4. FAU NeW - Research Center New Bioactive Compounds, University of Erlangen-Nürnberg, Erlangen, Germany; 5. Comprehensive Cancer Center Erlangen-EMN (CCC ER- EMN), Erlangen, Germany; 6. Comprehensive Cancer Center Alliance WERA (CCC WERA), Erlangen, Germany; 7. Bavarian Cancer Research Center (BZKF), Erlangen, Germany

Source PDF DOI Publisher page
262 days

NPTXR as a novel therapeutic target: efficacy of antibody-drug conjugates in preclinical tumor models

AuthorsMykola Lyndin; Michel Janicot; Justus Müller; Peter Schiemann; Gunther Wennemuth

Affiliations1. Department of Anatomy, University of Duisburg-Essen, Medical Faculty, Essen, Germany; 2. Ymmunobio AG, Riehen, Switzerland

Source PDF DOI Publisher page
233 days

Quantifying target antigen-dependent CAR T-cell performance against AML

AuthorsSaumil Shah; Jan Mueller; Emanuel Vogel; Michael Raatz; Steffen Boettcher; Arne Traulsen; Markus G. Manz; Philipp M. Altrock

Affiliations1. Department of Theoretical Biology, Max Planck Institute for Evolutionary Biology, Plön, Germany; 2. Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland; 3. Department of Internal Medicine V, Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria; 4. Department of Hematology and Oncology, Kiel University and University Hospital Schleswig-Holstein, Kiel, Germany; 5. Clinical Research Unit CATCH ALL (KFO 5010), Kiel, Germany

Source PDF DOI Publisher page
168 days

The oral microbiota in oral squamous cell carcinoma: unravelling mechanisms and clinical potential

AuthorsAmany Hany Mohamed Kamel; Nourhan El-Tantawy; Sarah Ahmed; Al-Hassan Soliman Wadan; Nermeen AbuBakr

Affiliations1. Oral Biology Department, Faculty of Dentistry, Cairo University, Cairo, Egypt; 2. Oral Biology Department, Faculty of Dentistry, Delta University, Mansoura, Egypt; 3. Ministry of Health and Population, Cairo, Egypt; 4. Oral Biology Department, Faculty of Dentistry, Galala University, Suez, Egypt

Source PDF DOI Publisher page
235 days

CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions

AuthorsDuc-Hiep Bach; Van T. Hoang; Thi Viet Pham; Huong; Dinh Duy Nguyen; Thanh Liem Nguyen

Affiliations1. Vinmec Research Institute of Stem Cell and Gene Technology, College of Health Sciences, Hanoi, Vietnam; 2. Vinmec International Hospital, Vinmec Health Care System, Hanoi, Vietnam

Source PDF DOI Publisher page
267 days

Integrative plasma-to-spatial proteomics reveals fibroblast-associated signatures in liver metastatic breast cancer

AuthorsElif Öcal; Janik Riese; Ursula Schneider; Mark P. Kühnel; Danny Jonigk; Heidrun Hirner-Eppeneder; Stefanie Corradini; Osman Öcal; S. Nahum Goldberg; Max Seidensticker; Jens Ricke; Moritz Wildgruber; Marianna Alunni-Fabbroni

Affiliations1. Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany; 2. Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; 3. Institute of Pathology, Aachen University Hospital, Aachen, Germany; 4. Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Aachen, Germany; 5. Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany; 6. Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany; 7. Department of Radiology, Hadassah Hebrew University Medical Center, Jerusalem, Israel

Source PDF DOI Publisher page
168 days

Macrophage-derived CTSZ promotes prostate cancer progression via αVβ3 integrin-mediated activation of the AKT/FOXO1/JUNB signaling axis

AuthorsYouxin Liu; Saipeng Chen; Jie Xu; Hang Yuan; Hanzi Yang; Bingqian Deng; Jie Feng; Heting Liu; Langlang Xie; Gang Huang; Wenhao Shen

Affiliations1. Department of Urology, Southwest Hospital, Army Medical University, Third Military Medical University, Chongqing, China; 2. Department of Urology, The 968th Hospital of Joint Logistics Support Force of PLA, Jinzhou, China; 3. Department of Biochemistry and Molecular Biology, College of Basic Medical Science, Army Medical University, Third Military Medical University, Chongqing, China

Source PDF DOI Publisher page
206 days

Integrative analysis of SLFN11-related DEGs reveals novel biomarkers for cisplatin sensitivity and immune modulation in colorectal cancer

AuthorsWei Wang; Lijiang Zhou; Jing Wang; Tingting Li; Zheng Li

Affiliations1. Department of Integrated Chinese and Western medicine, Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute), Shenyang, China; 2. Department of Oncology, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China; 3. Traditional Chinese medicine oncology, Liaoning University of Traditional Chinese Medicine, Shenyang, China

Source PDF DOI Publisher page
74 days

The novel oleanolic acid derivative ZQL-4c modulates trastuzumab resistance in HER2+ breast cancer by inhibiting SCD-mediated lipid metabolism disorders

AuthorsYiwen Ma; Shisheng Wang; Xiaorui Li; Xiangyu Guo; Cui Jiang; Tao Sun

Affiliations1. Breast Internal Medicine Ward 1, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China; 2. Breast Internal Medicine Ward 1, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China; 3. College of Pharmaceutical Science and Technology, Dalian University of Technology, Dalian, China

Source PDF DOI Publisher page
189 days

In silico repurposing of clinically approved drugs as potential BRAF inhibitors: a pharmacophore-based virtual screening and experimental investigation

AuthorsHooriehsadat Amini; Negin Ebrahimi; Sayedali Mousavirahimi; Mozhdeh Zamani; Kowsar Bagherzadeh; Hamed Montazeri; Homa Azizian

Affiliations1. Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; 2. Protein Chemistry and Proteomics Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran; 3. Student Research Committee, Iran University of Medical Sciences, Tehran, Iran; 4. Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran; 5. Eye Research Center, Five Senses Health Institute, Moheb Kowsar Hospital, Iran University of Medical Sciences, Tehran, Iran; 6. Lyon Cancer Research Center, Centre Léon Bérard, University Claude Bernard Lyon 1, INSERM U1052–CNRS UMR5286, Lyon, France; 7. Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran; 8. Artificial Intelligence in Health Research Institute, Iran University of Medical Sciences, Tehran, Iran; 9. Department of Medicinal Chemistry, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran

Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review96.4 days

Median77 days

Contact CrushSCI

Contact CrushSCI

Leave your contact details so we can discuss your manuscript, editing needs, and submission plan.

Selected service: Paper Editing Service

Or leave your contact details

WhatsApp, Telegram, WeChat, and email are all optional, but at least one is required. Once received, we will contact you as soon as possible.